Literature DB >> 11862362

Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?

M J Morgan1, L McFie, H Fleetwood, J A Robinson.   

Abstract

RATIONALE: Chronic, regular recreational use of ecstasy (MDMA) is associated with psychopathology, elevated behavioural impulsivity and persistent impairment of memory performance.
OBJECTIVE: The aim of the present study was to investigate which of these sequelae persist after at least 6 months of abstinence from ecstasy.
METHODS: Four groups of participants were compared: 18 current regular recreational ecstasy users, 15 ex-regular ecstasy users who had abstained from using the drug for an average of 2 years, 16 polydrug users who had never taken ecstasy and 15 drug-naive controls.
RESULTS: There were no significant group differences in age, education level, or pre-morbid intelligence and, generally, the use of illicit drugs other than ecstasy was not significantly different among the three drug-using groups. Both current and ex-ecstasy users exhibited elevated psychopathology and behavioural impulsivity compared with polydrug users and drug-naive controls, but current ecstasy users exhibited a broader range of psychopathology than ex-users. Both groups of ecstasy users also exhibited impaired working memory and verbal recall performance compared with drug-naive controls, but only ex-users exhibited impaired verbal recall relative to polydrug users. Regression analysis indicated that psychopathology was primarily predicted by the extent of previous consumption of cannabis rather than ecstasy, whereas the majority of the cognitive deficits were only predicted by the extent of previous ecstasy use.
CONCLUSIONS: Selective impairments of neuropsychological performance associated with regular ecstasy use are not reversed by prolonged abstinence. This is consistent with evidence that ecstasy has potent and selective neurotoxic effects on brain serotonergic systems in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11862362     DOI: 10.1007/s002130100907

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  48 in total

1.  Ecstasy use and suicidal behavior among adolescents: findings from a national survey.

Authors:  Jueun Kim; Bin Fan; Xinhua Liu; Nancy Kerner; Ping Wu
Journal:  Suicide Life Threat Behav       Date:  2011-06-01

2.  fNIRS suggests increased effort during executive access in ecstasy polydrug users.

Authors:  C A Roberts; C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2014-11-14       Impact factor: 4.530

Review 3.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

4.  Effects of ecstasy/polydrug use on memory for associative information.

Authors:  Denis T Gallagher; John E Fisk; Catharine Montgomery; Jeannie Judge; Sarita J Robinson; Paul J Taylor
Journal:  Psychopharmacology (Berl)       Date:  2012-08       Impact factor: 4.530

5.  A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users.

Authors:  Daniel Wagner; Philip Koester; Benjamin Becker; Euphrosyne Gouzoulis-Mayfrank; Martin Hellmich; Joerg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2014-08-27       Impact factor: 4.530

6.  The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Authors:  Maartje M L De Win; Gerry Jager; Hylke K E Vervaeke; Thelma Schilt; Liesbeth Reneman; Jan Booij; Frank C Verhulst; Gerard J Den Heeten; Nick F Ramsey; Dirk J Korf; Wim Van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

7.  The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory.

Authors:  Catharine Montgomery; John E Fisk; Russell Newcombe; Phillip N Murphy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

8.  Chronic cognitive impairment in users of 'ecstasy' and cannabis.

Authors:  Anthony Klugman; John Gruzelier
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

9.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

10.  Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.

Authors:  Krista Lisdahl Medina; Paula K Shear
Journal:  Drug Alcohol Depend       Date:  2006-10-30       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.